Aro Biotherapeutics, a clinical-stage biotechnology company developing potent and tissue-targeted short-interfering RNA (siRNA) medicines, today announced interim data from a phase 1b study of ABX1100 ...

Partnership launched under MTEA to evaluate the potential of Vect-Horus technology to deliver siRNAs into the CNSAssessment ...

Under the agreement, SanegeneBio has granted Genentech exclusive worldwide rights to develop and commercialize the undisclosed program.

The deal provides SanegeneBio with an upfront payment of $200m.

Discover how a newly developed platform technology from The University of North Carolina at Chapel Hill can enhance RNAi ...

The current coronavirus disease 2019 (COVID-19) pandemic, caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), has challenged healthcare facilities globally. Even though the FDA ...

siMecA-AGO2 complex inhibits the translation of the mecA gene which encodes the penicillin-binding protein 2a (PBP2a), a protein at the heart of the drug-resistance phenotype in MRSA. By reducing ...

SYDNEY--(BUSINESS WIRE)--Novotech, a globally recognized full-service clinical research organization (CRO) and scientific advisory company, has released its newest preclinical report exploring the ...

Alnylam has set out how it plans to deliver siRNA to the central nervous system and other tissues beyond the liver. Writing in Nature Biotechnology, the RNA specialist shared details of how the ...

Alnylam Pharmaceuticals and PeptiDream are partnering to develop a peptide-based delivery system for Alnylam’s small interfering RNA (siRNA) therapies that silence gene expression. Alnylam has three ...